Funded Startups in Herzliya
In Herzliya’s most recent funded rounds (50 rows), one disclosed deal stands far above the rest: Solegreen’s $149M round closed on 2023-01-06.
In Herzliya’s most recent funded rounds (50 rows), one disclosed deal stands far above the rest: Solegreen’s $149M round closed on 2023-01-06. The next-largest disclosed amount is BlueWind Medical at $48M (2026-05-14), making Solegreen’s disclosed figure a clear outlier versus every other disclosed round in the list. The entries also cluster temporally into two dense windows: five rounds with disclosed amounts fall between 2025-11-01 and 2025-11-20 (including Localbird’s $7M on 2025-11-20, Mate’s $16M on 2025-11-19, and Tenzai’s $75M on 2025-11-16), and another concentration shows up in 2026-02 to 2026-04 with multiple disclosed deals such as Hypercore’s $14M (2026-02-23) and NeuroSense Therapeutics’ $600K (2026-04-28).
Sector and stage disclosures skew toward repeat categories and partially undisclosed terms: “Artificial Intelligence (AI)” appears in 14 entries, and “Series Unknown” is used in 29 entries, alongside 4 “undisclosed” amounts. The most recent round date in these rows is 2026-06-22 (InterCure, $7M), while the oldest shown is 2021-07-01 (Juno Journey, $19M).
Most recent rounds
50 of 566 more funded startups
This page shows the 50 most recent rounds (back to Jul 2021). The full 56-company history for this listing is available on a paid plan.
Unlock all 56 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
How extreme is the largest disclosed round in this Herzliya set, and what comes next?
Solegreen’s $149M on 2023-01-06 dwarfs the field; the next-largest disclosed amount is BlueWind Medical’s $48M on 2026-05-14. Most other disclosed rounds sit well below $50M—for example, Tenzai is $75M on 2025-11-16, while several are in the $2M–$25M range such as Firefly Neuroscience ($2M, 2026-03-08) and Hypercore ($14M, 2026-02-23).
Are there noticeable timing clusters among the most recent entries?
Yes. Between 2025-11-01 and 2025-11-20, multiple disclosed rounds land within the same month, including Localbird ($7M, 2025-11-20), Mate ($16M, 2025-11-19), and Tenzai ($75M, 2025-11-16). A second cluster spans 2026-02 through 2026-04 with several disclosed rounds such as Hypercore ($14M, 2026-02-23), Winn ($18M, 2026-02-11), and NeuroSense Therapeutics ($600K, 2026-04-28).
What sectors are most over-represented in this list, and how does that intersect with deal size?
Artificial Intelligence (AI) is the most frequent sector with 14 entries, and it includes both large disclosed rounds (Tenzai $75M on 2025-11-16; Hypernative $40M on 2025-06-10) and smaller tickets like Firefly Neuroscience at $2M (2026-03-08) and BrandShield at $3M (2023-10-24). By contrast, Biotechnology appears repeatedly but is less concentrated in size than AI—for instance, BlueWind Medical is $48M (2026-05-14) and NeuroSense Therapeutics is $600K (2026-04-28).
How dominant is ‘Series Unknown’ or undisclosed amounts, and does that affect outlier detection?
Disclosure is uneven: 29 of the 50 rows are labeled “Series Unknown,” and 4 rows show “undisclosed” amounts (e.g., aiOla at 2025-11-04; Noma at 2025-06-05; StoreDot at 2025-05-12; TerraZone at 2024-11-01). As a result, comparisons of maximum/minimum deal size rely only on disclosed amounts; within that subset, Solegreen’s $149M (2023-01-06) remains the standout disclosed outlier.
Within the most recent 90 days of the latest round date shown, which disclosed deals stand out?
Using the latest date in the table (2026-06-22), the most recent 90-day window includes disclosed rounds like BlueWind Medical ($48M, 2026-05-14), InterCure ($7M, 2026-06-22), and Third Eye Systems ($10M, 2026-04-14). It also contains smaller disclosed deals close to the window such as Firefly Neuroscience ($2M, 2026-03-08) and InnoCan Pharma ($450K, 2026-03-07).
Is there a clear low-end outlier among disclosed amounts, and what’s the smallest disclosed figure here?
The smallest disclosed amount in the rows is NeuroSense Therapeutics at $600K on 2026-04-28. That sub-$1M ticket is lower than other small disclosed deals in the list, such as Firefly Neuroscience’s $2M (2026-03-08) and BrandShield’s $3M (2023-10-24), making NeuroSense a low-end outlier within disclosed amounts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.